BerGenBio and Tempus Collaborate to Advance the Development of STK11m to Treat NSCLC
Shots:
- BerGenBio entered into a collaboration with Tempus to advance the development of selective AXL inhibitor bemcentinib as a 1L treatment for NSCLC-induced patients with STK11 mutations (STK11m)
- To support BerGenBio's study, the collaboration will provide access to Tempus' tailored clinical and molecular data. Tempus’ AI-enabled platform will allow BerGenBio to analyze the data and enhance understanding of the genomic landscape and treatment responses
- Currently, the drug is evaluating in the BGBC016 P-Ib/IIa study assessing the advantage of adding bemcentinib to the current SoC medication (immunotx. + doublet CT) in people with poor outcomes
Ref: BerGenBio | Image: BerGenBio & Tempus
Related News:- BerGenBio Reports P-II Trial Results of BGB324 (bemcentinib) as 2L Treatment of Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
